Gluten immunogenic peptide excretion detects dietary transgressions in treated celiac disease patients
| Autor: | Eduardo Mauriño, Horacio Vázquez, Julio C. Bai, Sonia I. Niveloni, M Remedios Domínguez-Flores, Emilia Sugai, Angel Cebolla-Ramirez, Elena F. Verdu, Alba Muñoz-Suano, María de la Paz Temprano, Ana F. Costa, Edgardo Smecuol, María Laura Moreno, Juan Pablo Stefanolo, Andrea F. Gonzalez |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Glutens Point-of-care testing Rapid tests Observational Study Enzyme-Linked Immunosorbent Assay Urine Disease Asymptomatic Gastroenterology Excretion Diagnostic Self Evaluation Diet Gluten-Free Feces Surveys and Questionnaires Internal medicine Intestinal Elimination Humans Celiac disease Medicine In patient Prospective Studies Aged Aged 80 and over chemistry.chemical_classification business.industry Follow-up General Medicine Middle Aged Immunogenic peptide Gluten Gluten immunogenic peptide excretion Cross-Sectional Studies chemistry Point-of-Care Testing Asymptomatic Diseases Gluten-free diet Patient Compliance Female medicine.symptom Peptides business |
| Zdroj: | World Journal of Gastroenterology |
| ISSN: | 1007-9327 |
| Popis: | Background Life-long removal of gluten from the diet is currently the only way to manage celiac disease (CeD). Until now, no objective test has proven useful to objectively detect ingested gluten in clinical practice. Recently, tests that determine consumption of gluten by assessing excretion of gluten immunogenic peptides (GIP) in stool and urine have been developed. Their utility, in comparison with conventional dietary and analytical follow-up strategies, has not been fully established. Aim To assess the performance of enzyme-linked immunosorbent assay (ELISA) and point-of-care tests (PoCTs) for GIP excretion in CeD patients on gluten-free diet (GFD). Methods We conducted an observational, prospective, cross-sectional study in patients following a GFD for at least two years. Using the Gastrointestinal Symptom Rating Scale questionnaire, patients were classified at enrollment as asymptomatic or symptomatic. Gluten consumption was assessed twice by 3-d dietary recall and GIP excretion (by ELISA in stool and PoCTs (commercial kits for stool and urine) in two consecutive samples. These samples and dietary reports were obtained 10 day apart one from the other. Patients were encouraged to follow their usual GFD during the study period. Results Forty-four patients were enrolled, of which 19 (43.2%) were symptomatic despite being on a GFD. Overall, 83 sets of stool and/or urine samples were collected. Eleven out of 44 patients (25.0%) had at least one positive GIP test. The occurrence of at least one positive test was 32% in asymptomatic patients compared with 15.8% in symptomatic patients. GIP was concordant with dietary reports in 65.9% of cases (Cohen´s kappa: 0.317). PoCT detected dietary indiscretions. Both ELISA and PoCT in stool were concordant (concomitantly positive or negative) in 67 out of 74 (90.5%) samples. Excretion of GIP was detected in 7 (8.4%) stool and/or urine samples from patients considered to be strictly compliant with the GFD by dietary reports. Conclusion GIP detects dietary transgressions in patients on long-term GFD, irrespective of the presence of symptoms. PoCT for GIP detection constitutes a simple home-based method for self-assessment of dietary indiscretions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|